NCLT Order Advances JBCPL-Torrent Pharma Merger

The National Company Law Tribunal (NCLT), Ahmedabad Bench, has uploaded its order concerning the first motion application for the proposed merger of J.B. Chemicals & Pharmaceuticals Limited (JBCPL) with Torrent Pharmaceuticals Limited. This filing, dated March 23, 2026, marks a key procedural step forward in the amalgamation process, which was first announced on June 29, 2025.

Why the NCLT Order Matters

The NCLT's approval of the first motion application is a critical milestone. It allows the merger process to proceed to the next stages, which typically involve convening meetings of JBCPL shareholders and creditors to secure their consent for the proposed scheme of arrangement. This clearance is essential for navigating regulatory hurdles and moving closer to finalizing the merger between the two pharmaceutical firms.

Background of the Merger Deal

Torrent Pharmaceuticals announced its intention to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals from global investment firm KKR on June 29, 2025. The total transaction was valued at ₹25,689 crore on a fully diluted basis. The deal began with Torrent acquiring a 46.39% stake from KKR for ₹11,917 crore (at ₹1,600 per share), along with plans for a mandatory open offer for an additional 26% of public shareholding at ₹1,639.18 per share.

Torrent completed the acquisition of its initial stake in JB Pharma on January 21, 2026, taking on controlling promoter status. The merger plan includes a share-swap ratio where every 100 JBCPL shares will be exchanged for 51 Torrent Pharma shares. The amalgamation requires several statutory approvals, including from SEBI, stock exchanges, the Competition Commission of India (CCI), and the NCLT. The CCI had cleared the proposed acquisition in October 2025.

What the NCLT Approval Means

The uploaded NCLT order facilitates the continuation of the amalgamation process, moving towards seeking shareholder approval. This clears one of the key regulatory gates in the complex merger procedure, paving the way for the eventual integration of JBCPL into Torrent Pharma and the creation of a larger combined entity. It also keeps the share swap ratio under close watch for JBCPL shareholders as the merger progresses.

Key Risks to Monitor

J.B. Chemicals has faced significant Goods and Services Tax (GST) penalties, including ₹80.81 crore from Tamil Nadu authorities and ₹41 crore from Central GST, Ahmedabad, for alleged tax discrepancies and wrongful refund claims. The company intends to appeal these orders.

Torrent Pharmaceuticals has received demand notices from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging on drug products, totaling ₹6.63 crore and ₹60.28 lakh in separate instances.

Additionally, Torrent Pharma has faced scrutiny from the U.S. Food and Drug Administration (FDA), including a warning letter in 2019 and a Form 483 in 2022 for Current Good Manufacturing Practice (cGMP) violations and other issues at its manufacturing facilities. The merger also remains subject to final sanctions from the NCLT and other regulatory bodies, which may involve further procedural steps and timelines.

Industry Context

J.B. Chemicals and Torrent Pharmaceuticals operate within India's strong pharmaceutical sector. They compete with major players such as Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's Laboratories, often vying on product portfolios, research and development capabilities, and market expansion strategies. Sun Pharma, as India's largest pharma company, and Dr. Reddy's, known for its R&D focus, set industry benchmarks for scale and innovation. The proposed merger aims to position the combined entity more competitively within this landscape.

Transaction Milestones

• The amalgamation was first announced on June 29, 2025, with an initial stake acquisition valued at ₹11,917 crore.
• The overall equity valuation for J.B. Chemicals & Pharmaceuticals in the deal was stated as ₹25,689 crore on a fully diluted basis.

What to Track Next

• NCLT Final Sanction: Awaiting the full order details and subsequent steps for the second motion petition at the NCLT.
• Shareholder & Creditor Meetings: Confirmation of dates and outcomes for meetings to approve the scheme of arrangement.
• Further Regulatory Approvals: Final clearances from other statutory bodies, if any.
• Scheme Implementation: Timelines for the actual share swap and the subsequent integration of operations between Torrent Pharma and JBCPL.